Panacea Biotec Ltd has received a significant Letter of Award from UNICEF to supply 115 million doses of its bivalent oral polio vaccine (bOPV) for the calendar year 2025. The total contract value is approximately $14.95 million (~₹127 crore).
Key Highlights:
- Order Details: The agreement involves supplying bOPV to UNICEF for its vaccine programs across Africa and Asia, aimed at addressing critical healthcare needs in these regions.
- Execution Period: The supply will be completed within the calendar year 2025.
- International Contract: The order is awarded by UNICEF, marking Panacea Biotec’s contribution to global health initiatives.
- Value: The award is valued at ~₹127 crore, emphasizing the company’s capability in delivering high-quality vaccines for large-scale international requirements.
Strategic Importance:
This order further strengthens Panacea Biotec’s position as a key player in global healthcare and aligns with its mission to support large-scale immunization programs. The supply is expected to boost the company’s international revenue stream and reinforce its reputation in vaccine manufacturing.
The contract is subject to the signing of requisite amendments to the existing Long-Term Arrangement with UNICEF. Panacea Biotec has confirmed that there is no involvement of promoter or related party transactions in this contract.
